Status legend
Statuses are as of 1 October 2026 and are kept as the brochure prints them. The brochure uses four labels:
- OPEN — available or accepting applications
- CLOSING — a stated window or period ends on the date shown
- CLOSED — no new applicants
- ANNOUNCED — announced or approved; check operating guidelines
Notified guidelines govern eligibility. Budget announcements need operating guidelines before applications open. The PLI schemes have selected their beneficiaries, so new entrants gain mainly through the parks, the device sub-schemes and state policies.
Production incentives and parks
| Scheme | What the investor gets | Who qualifies | Status |
|---|---|---|---|
| PLI for pharmaceuticals (₹15,000 crore) | Incentive on incremental sales, 2022-23 to 2027-28: 10% (years 1–4), 8% and 6% for categories 1 and 2; 5%, 4% and 3% for category 3. Ceiling ₹1,000 crore per Group A applicant; ₹5,433 crore paid by October 2025. | 55 selected applicants, including 20 MSMEs | 55 SELECTED; INCENTIVES END FY2027-28 |
| PLI for bulk drugs: KSMs, intermediates, APIs (₹6,940 crore) | Incentive on sales of notified products for six years: fermentation-based 20% (FY2023-24 to FY2026-27), then 15% and 5%; chemical synthesis 10% (FY2022-23 to FY2027-28). | 48 approved projects covering 33 products | 48 APPROVED; INCENTIVES END FY2028-29 |
| PLI for medical devices (₹3,420 crore) | 5% of incremental sales of target-segment devices made in India for five years, capped at ₹121 crore (Category A) or ₹40 crore (Category B) per applicant. | Selected greenfield projects only | SELECTION DONE; INCENTIVES TO FY2026-27 |
| Bulk Drug Parks (₹3,000 crore) | Plots in parks at Jambusar (Gujarat), Nakkapalli (Andhra Pradesh) and in Himachal Pradesh, with shared infrastructure built with a central grant to the state agency of 70% of cost (90% in specified states), up to ₹1,000 crore a park. | API makers locating in the three parks | Extended to FY2026-27 on 23 Jun 2025 |
| Medical Device Parks (₹400 crore) | Plots with shared infrastructure and testing, built with a central grant to the state agency of 70% of cost (90% in specified states), up to ₹100 crore a park. By Sep 2025, 194 makers had land in the UP, MP and TN parks. | Device makers taking plots in the approved parks | Budget 2026-27: ₹50 crore; extension sought |
| Strengthening of the Medical Device Industry (₹500 crore) | Five sub-schemes: components and raw materials (₹180 crore), common facilities and test labs (₹110 crore), clinical studies (₹100 crore), skills (₹100 crore) and promotion (₹10 crore). | Device makers, clusters and institutions, by sub-scheme | Launched 8 Nov 2024; 10 component projects approved |
Sources: Department of Pharmaceuticals Annual Report 2025-26; DoP Guidelines, Promotion of Medical Device Parks; Invest India pharmaceuticals and medical devices pages (retrieved 1 Oct 2026).
R&D, upgrade and biopharma schemes
R&D and upgrade calls have run in windows; biopharma money awaits guidelines.
| Scheme | What the investor gets | Who qualifies | Status |
|---|---|---|---|
| Revamped Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS) | Subsidy of 20%, 15% or 10% of investment in upgrading to revised Schedule M or WHO-GMP, by turnover band (₹1–50 crore, ₹50–250 crore, ₹250–500 crore), up to ₹2 crore a unit. | Existing pharma units with turnover up to ₹500 crore | Period FY2024-25 to FY2025-26; 255 approved |
| Promotion of Research and Innovation in Pharma-MedTech (PRIP, ₹5,000 crore) | Early-stage projects of start-ups and MSMEs: up to ₹5 crore, fully funded up to ₹1 crore. Later-stage projects: milestone-based support of up to 35% of project cost or ₹100 crore, whichever is lower. | Industry, MSMEs and start-ups in priority areas | Call closed 19 Nov 2025; 710 applications |
| Biopharma SHAKTI (₹10,000 crore over five years) | Ecosystem for domestic production of biologics and biosimilars: three new NIPERs, seven upgraded, over 1,000 accredited clinical-trial sites and a scientific review cadre at CDSCO. | To be set out in operating guidelines | BUDGET 1 FEB 2026; GUIDELINES AWAITED |
| Research, Development and Innovation (RDI) Scheme (₹1 lakh crore) | Long-term finance or refinancing at low or nil interest for private R&D, routed through second-level fund managers such as AIFs; also a Deep-Tech Fund of Funds. | Companies investing in R&D, through the fund managers | Approved Jul 2025; fund launched Nov 2025 |
| BioE3 policy and Bio-RIDE (Department of Biotechnology) | BioE3 supports biomanufacturing, Bio-AI hubs and biofoundries; Bio-RIDE merged two DBT umbrella schemes to fund research, innovation and entrepreneurship. | Biotech companies, start-ups and research bodies | BioE3 approved Aug 2024; Bio-RIDE Sep 2024 |
| Regional medical value tourism hubs | A scheme to support states in setting up five regional medical hubs with the private sector, combining care, education and research with AYUSH centres, diagnostics and rehabilitation. | States, with private partners | BUDGET 1 FEB 2026 |
Sources: DoP Annual Report 2025-26; Budget speech 2026-27, paras 16 and 55; PIB Budget note on biopharma, Feb 2026; India Pharma Outlook, 2026; PIB, RDI Scheme, Jul 2025.
What this means for a new entrant
- PLI places are allocated. The pharma PLI (55 selected), bulk-drug PLI (48 projects) and device PLI (selection done) are closed to new applicants. Approved companies continue to lodge PLI claims until their scheme’s incentive period ends (FY2027-28 for pharma, FY2028-29 for bulk drugs, FY2026-27 for devices).
- Parks are the main open route for manufacturers. Bulk drug parks at Jambusar, Nakkapalli and in Himachal Pradesh, and device parks in Uttar Pradesh, Madhya Pradesh and Tamil Nadu, offer plots with shared infrastructure and testing. Bulk drug parks were extended to FY2026-27 on 23 June 2025 and Budget 2026-27 provides ₹700 crore; device parks have ₹50 crore in Budget 2026-27 with an extension to March 2028 sought.
- Device sub-schemes remain live. The ₹500 crore Strengthening of the Medical Device Industry scheme, launched 8 November 2024, funds components, common facilities, clinical studies, skills and promotion; ten component projects are approved.
- Watch for new windows. The last PRIP call closed on 19 November 2025 with 710 applications. RPTUAS’s approved period ended in FY2025-26, though ₹250 crore is in Budget 2026-27. Biopharma SHAKTI cannot be applied for until operating guidelines are issued.
- RDI finance runs through fund managers. The ₹1 lakh crore RDI Scheme, approved July 2025 with its fund launched November 2025, reaches companies through second-level fund managers such as AIFs rather than direct application.
Track status changes on the incentive tracker and the updates feed. The master list of central schemes across sectors is on central schemes.
What to check next
- Confirm with the Department of Pharmaceuticals whether any new PRIP call or RPTUAS window has opened since 1 October 2026.
- Check whether Biopharma SHAKTI operating guidelines have been issued before planning a biologics project around it.
- For a park site, confirm plot availability with the state agency and the park’s extension status.
- If acquiring a PLI beneficiary, verify its category, remaining incentive years and the ceiling already used.
- For device makers, identify which of the five sub-schemes fits, and whether a cluster or institution must apply.